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Abstract
Background: Foot complaints are common in inflammatory arthropathies such as rheumatoid arthritis and cause
considerable disability. However, little is published about the nature and extent of foot complaints in systemic lupus
erythematosus (SLE). We aimed to explore foot complaints among people with (SLE) and to evaluate the associations
between foot pain and self-reported activities of daily living and well-being.
Methods: We developed and tested a new 40-item item self-administered questionnaire, using a five-stage development
process utilising patient involvement throughout to ensure face and content validity. The self-administered instrument
was posted to 406 people with SLE attending adult rheumatology clinics across three health boards in Auckland,
New Zealand. The questionnaire enquired about symptoms of foot pain, extra-articular features, anatomical distribution
of symptoms according to validated foot-mannequins and the impact of foot symptoms on activities of daily living
and well-being.
Results: In total, 406 questionnaires were posted, with 131 responses (response rate 32 %). We found 89 % were
women, mean (SD) age 51 (15) years, mean (SD) diagnosis 12.5 (11.1) years. Overall, 77 % of those responding to
the questionnaire reported foot pain during their SLE, with 45 % reporting current foot pain. All regions of the
feet were affected, with the hindfoot (32 %) and ankles (30 %) most troublesome. The most common self-reported
extra-articular foot complaints were cold feet, swelling and numbness. Almost two-thirds (61 %) reported foot pain
adversely affected their lives; foot pain prevented sleeping in 36 % and had a negative effect on emotions for 33 %.
Only 33 % of participants had seen a podiatrist. Significant association was found between foot pain and standing
longer than 15 min (p < 0.001), walking (p < 0.001), climbing stairs (p < 0.001) and going shopping (p < 0.001).
Pain was the primary symptom to affect quality of life (47/100).
Conclusion: Foot complaints in SLE are heterogeneous in nature, and may have a substantial negative impact on
patient well-being. Foot complaints need to be addressed to reduce the burden of SLE and our findings support
the need for wider access to specific foot care services.
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Background
Systemic lupus erythematosus (SLE) is a chronic, systemic,
autoimmune disease that can lead to substantial multi-
organ pathology [1, 2]. SLE is clinically heterogeneous;
typically with a relapsing and remitting course having a
negative effect on health, quality of life, career develop-
ment and raising a family [3–5]. SLE is more prevalent
among those with an African, Asian or Polynesian ancestry
[1, 6]. There remain considerable unmet medical needs for
people with SLE [4]; yet the prevalence of foot complaints
in SLE is reportedly high, with 67 % of SLE participants
having arthropathy in the feet [7]. A recent ultrasound im-
aging study found greater foot involvement than hand
involvement in SLE with 73 % of participants presenting
with inflammatory foot joint abnormalities [8]. These in-
cluded; joint effusion, synovial hypertrophy and positive
power Doppler signals [8]. Furthermore, patients with SLE
are reported to be at greater risk of reporting complica-
tions due to vascular pathology secondary to accelerated
atherosclerosis [9, 10]. Previous studies have found periph-
eral vascular disease (PVD) to be widespread among
people with SLE, with a prevalence rate between 13 and
28 % [11, 12]. In the lower limb, low ankle brachial pres-
sure indices, a key indicator of PVD, were found in 37 %
of a UK study [13] and 21 % in a Swedish cohort [14].
Critical ischaemia, foot ulceration, digital gangrene, and
Raynaud’s phenomenon have been reported in two
large retrospective studies [15, 16]. Despite the range of
reported pathologies affecting the feet, there remains a
lack of evidence defining the pattern of foot involve-
ment on function and quality of life in people with SLE.
Furthermore, a recent narrative review of foot complaints
in SLE also reported there is limited evidence on the epi-
demiology or treatment recommendations for foot disease
in SLE [17]. We aimed to explore self-reported foot com-
plaints among people with SLE and to evaluate associations
between reported foot pain and clinical characteristics, spe-
cifically activities of daily living well-being.
Method
Subjects and setting
Participants were identified using Auckland, Counties
Manukau and Waitemata District Health Board databases
in Auckland, New Zealand. The Systemic Lupus Inter-
national Collaborating Clinics (SLICC) classification cri-
teria [18] were not used to identify potential participants,
as this criteria is not used locally for diagnosis. Therefore,
participants eligible for the study were >18 years old, had
a positive diagnosis of SLE as determined by their consult-
ant rheumatologist and had attended a rheumatology
clinic for their SLE in the previous 2 years. Analysis of the
rheumatology database enabled us to exclude those with
juvenile SLE and other concomitant inflammatory ar-
thropathies. Participants with undifferentiated connective
tissue disorders and overlap syndromes were also ex-
cluded. Ethical approval was granted by Auckland Univer-
sity of Technology Ethics Committee.
Data generation
Data were generated from a questionnaire (Additional file
1) designed to collect information relating to demographic
and clinical characteristics’ that included: age, sex, body
mass index (BMI), ethnicity, employment status, current
medications, smoking status, SLE disease duration and
morning stiffness. Details of questionnaire development
process are provided in Additional file 2 with data from
our pilot study in Additional file 3. The anatomical loca-
tion of foot pain using three different case definitions (cur-
rently, during the past month and ever during the course
of SLE) were recorded with the use of validated foot man-
nequins [19]. The severity of foot pain was assessed with
using a 10 cm Visual Analogue Scale (VAS). The self-
reported presence of vascular, neurological and cutaneous
extra-articular features complaints affecting the feet was
also recorded. The effect of foot complaints on partici-
pants’ well-being was captured by enquiring about sleep
and emotion. The impact of foot symptoms on activities
of daily living (walking, shopping, climbing stairs, wearing
different shoes) as well as family and social activities
were reported. The assessment foot pain, need for foot
care and any foot-specific treatment received was also
recorded. We also used a SLE quality of life question-
naire (the Lupus QoL) a 34-item questionnaire across
eight domains (physical health, pain, planning, intimate
relationships, burden to others, emotional health, body
image and fatigue) [20]. Scores are computed to calcu-
late a total score from 0 (worst quality of life) to 100
(best quality of life) for each domain [20].
Data analysis
Data were entered into SPSS version 22 (IBM Inc.,
Armonk, New York, USA). Sex, ethnicity, work status,
smoking status and clinical characteristics of disease
duration, current pharmacological management, the lo-
cation of foot pain, and extra articular foot complaints
and the impact of foot complaints on activities of daily
living and the assessment/management of foot com-
plaints were reported as number (percentage). Other
demographic characteristics (age and BMI) together with
clinical characteristics of disease duration, early morning
stiffness and the severity of foot pain were reported as
mean (SD). Chi-square was used to determine associa-
tions between the presence of foot pain and categorical
variables of foot-related activities of daily living (stand-
ing, walking, climbing stairs, going shopping and wear-
ing different shoes). A level of significance was set at the
5 % level. Recommendations of the STROBE group [21]
were applied when reporting the findings.
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Results
In total, 406 questionnaires were posted with 131 re-
sponses (response rate 32 %). The demographic and clin-
ical characteristics are summarized in Table 1. Participants
were predominantly female (n = 117, 89 %), with mean
(SD) age 51 (15) years old and a mean (SD) disease dur-
ation of 12.5 (11.1) years. The majority of participants
were paid workers (n = 68, 52 %) and of New Zealand
European ethnicity (n = 67, 51 %).
We found 77 % (n = 99) of participants in this study re-
ported foot pain during the course of their disease, with
52 % (n = 68) reporting pain in the last month and 45 %
(n = 59) reporting current foot pain. For those participants
who reported current foot pain, the mean (SD) VAS score
was 4.9 (2.2) cm. No differences were found between foot
pain and age (p = 0.72), duration of SLE (p = 0.08), BMI
(p = 0.18), smoking (p = 0.15) or ethnicity (p = 0.37).
All parts of the foot were affected during the course of
the disease in our group, but overall, ankle (n = 40, 32 %)
and hind foot pain (n = 37, 30 %) predominated. However,
in those participants reporting current foot pain; digital
(n = 22, 17 %) and forefoot pain (n = 26, 20 %) was more
common than pain in the hind foot (Fig. 1). We found
91 % of participant’s self-reported joint pain as part of the
initial presentation of their SLE. While 35 % (n = 46) re-
ported their hands were affected initially, in contrast only
4 % (n = 5) reported pain in the feet as the first reported
symptom. During the course of the disease, pain in the
foot joints (n = 91, 71 %), pain in the arches of the feet
(n = 71, 55 %) or pain in tendons (n = 63, 49 %) was re-
ported by our participants (Table 2).
Respondents reported a wide range of extra-articular
complaints affecting their feet–summarised in Table 2.
The most common complaints were associated with vas-
cular changes. However, some features suggesting neuro-
logical deficit were reported. Cutaneous features that
included skin rashes on the feet/legs, blisters and foot
ulcers were not reported to be pathology in the majority
of cases.
Quality of life in general was adversely affected by foot
pain for 61 % (n = 78) of participants. Table 2 illustrates
that for many participants difficulties were reported with
standing for more than 15 min, walking, climbing stairs,
wearing different shoes and to a lesser extent going
shopping. Significant associations were found between
foot pain and standing longer than 15 min (p < 0.001),
walking (p < 0.001), climbing stairs (p < 0.001) and going
shopping (p < 0.001). Additionally, respondents reported
foot pain prevented sleep for 36 % (n = 47) of partici-
pants and 33 % (n = 43) reported foot pain had a nega-
tive effect on their emotions. The extent to which foot
complaints affected either family or social activities varied
considerably (Table 2). Pain was the primary symptom to
affect overall quality of life and received the lowest score
(Table 3). The domain with the highest score for quality of
life was emotional health.
In total, of 50 % (n = 66) of our respondents reported
that they had discussed their foot complaints with their
general practitioner and 49 % (n = 64) with their rheuma-
tologist. When asked to recall the most recent examin-
ation of their feet, respondents reported no difference
(p = 0.31) in the recalled time since foot examination
compared with the time since hand examination. Overall,
41 respondents (31 %) indicated they had difficulty under-
taking basic foot care, e.g. cutting toenails. Only 43 re-
spondents (33 %) reported ever having seen a podiatrist.
Twelve respondents (9 %) has seen a foot surgeon and 8
(6 %) undergone surgery. Overall, 29 respondents (22 %)
had been prescribed insoles with 14 respondents (11 %)
currently using foot orthoses and a further 15 respondents
reporting they had stopped using insoles (12 %).
Table 1 Demographic and clinical characteristics
Characteristic Value
Sex, n (%) Female: 117 (89)
Male: 14 (11)
Age (years), mean (SD) 51 (15)
Disease duration, mean (SD) 12.5 (11)
BMI (Kg/m2), mean (SD) 27.7 (6.4)
Current smoker, n (%) 27 (21)
Employment status, n (%)
Paid work 68 (52)
Not working 32 (24)
Retired 20 (15)
Unpaid work 5 (4)
Sick leave 2 (2)
Full-time education 3 (2)
Not stated 1 (1)
Ethnicity, n (%)
New Zealand European 71 (54)
Pacific Island 23 (18)
Asian 24 (19)
Māori 11 (8)
Early morning stiffness, n (%) 96 (68)
Early morning stiffness, duration, hours, mean (SD) 2.1 (5.4)
Hydroxychloroquine use, n (%) 97 (74)
Azathioprine use, n (%) 25 (19)
Methotrexate use, n (%) 19 (14)
Mycophenolate use, n (%) 6 (5)
Cyclophosphamide use, n (%) 3 (2)
Oral glucocorticoids use, n (%) 55 (42)
Non-steroidal anti-inflammatory drug use, n (%) 29 (22)
Rituximab use, n (%) 5 (4)
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Discussion
The findings from this study have shown that 77 % of par-
ticipants who responded to the questionnaire reported as
having experienced foot pain at some point during the
course of their SLE and 45 % reported experiencing foot
pain currently. Previous studies have reported articular in-
volvement to be the most common symptom in SLE with
prevalence rates between 83 and 95 % [22, 23]. Overall,
71 % of our participants reported pain in their foot joints.
However, clinical validation of this finding would be ap-
propriate given both the sampling frame used in this study
and the relative close proximity of anatomical structures
in the foot. When noting the location of their foot pain,
more of our participants reported rearfoot pain, in con-
trast to a similar study in rheumatoid arthritis where fore-
foot pain predominated [24]. Lagnocco et al. [8] reported
a high prevalence of forefoot pathology using ultrasonog-
raphy, but their work did not include hind foot joints. The
self-reported occurrence of foot pain in our study was
higher than in some clinically based studies of inflamma-
tory arthritis where soft tissue involvement is common
[25, 26]. The impact of foot pain on foot-related activities
of daily living, such as walking, were substantial in those













































Fig. 1 Frequency of pain reported by patients within different time descriptors at different anatomical sites in the foot. a Frequency of pain reported
ever during the course of the disease at different anatomical sites in the foot. b Frequency of pain reported in the last month at different anatomical
sites in the foot. c Frequency of pain reported today at different anatomical sites in the foot
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levels of foot pain may also contribute to the considerable
employment disability that has been previously been re-
ported with SLE [27]. Mancuso and colleagues [28] indi-
cated that for people with SLE, walking was the preferred
physical activity to improve their symptoms. Yet in our
sample, walking was adversely affected for over half of
respondents. Notably, foot pain was also reported to nega-
tively impact on social and family activities as well as sleep
and emotional health for substantial proportion of those
responding to the questionnaire, but did not reach statis-
tical significance. In parallel, results from the Lupus
Quality of Life questionnaire also indicated that increased
general pain resulted in low quality of life scores.
We found foot complaints likely to be caused by im-
paired vasculature were commonly reported by our partic-
ipants and included cold feet, Reynaud’s phenomenon and
chilblains. Bhatt et al. [11] indicated 30 % of their subjects
had Raynaud’s phenomenon, with 22 % previously re-
ported by Font et al. [22]. This is broadly in line with our
findings where 20 % reported Raynaud’s phenomenon was
always present and sometimes present for 38 %. It remains
unclear if numbness, which was a commonly reported
compliant, is frank clinical neuropathy. Previous studies
have suggested a prevalence of peripheral neuropathy
between 6 and 14 % in SLE using retrospective studies,
with not all of these cases being directly attributed to
SLE [29, 30].
Cutaneous lesions are common in SLE and are report-
edly the second most frequent finding after musculoskel-
etal symptoms [31] and muco-cutaneous lesions comprise
four of the 11 items of the revised SLICC criteria [18].
However, we found self-reported cutaneous lesions on the
feet were comparatively uncommon. Chilblains were the
most common cutaneous complaint, reported by up to
35 %, slightly greater than the 21 % reported in a UK study
[32]. The relative infrequency of cutaneous complaints
Table 2 Self-reported foot complaints in SLE (n, %)
Symptom reported Always Sometimes Never No response
Cold feet 57 (44) 57 (44) 11 (9) 4 (3)
Chilblains 8 (6) 37 (29) 72 (56) 12 (9)
Raynaud’s phenomenon 26 (20) 50 (38) 49 (38) 4 (3)
Intermittent claudication 16 (12) 54 (42) 57 (44) 2 (2)
Skin rash (legs or feet) 17 (13) 32 (25) 76 (59) 4 (3)
Blistering skin rash 7 (5) 19 (15) 98 (76) 5 (4)
Foot ulceration 1 (1) 18 (14) 106 (82) 5 (4)
Numbness 18 (14) 60 (47) 48 (37) 3 (2)
Loss of balance 6 (5) 42 (33) 77 (60) 4 (3)
Swelling 25 (19) 55 (43) 46 (36) 3 (2)
Joint pain 28 (22) 63 (49) 33 (26) 5 (4)
Arch pain 19 (15) 52 (40) 55 (43) 3 (2)
Tendon pain 17 (13) 46 (36) 63 (49) 3 (2)
Daily living activity
Standing >15 min 21 (16) 48 (38) 49 (38) 11 (9)
Walking 22 (17) 49 (38) 49 (38) 8 (6)
Climbing stairs 28 (22) 33 (26) 57 (56) 10 (8)
Wearing different shoes 24 (19) 42 (33) 54 (42) 8 (6)
Shopping 23 (18) 39 (31) 58 (45 8 (6)
Foot pain: family/social activities
Foot pain: social activities 38 (29) 51 (39) 41 (31) 1 (1)
Foot pain: family activities 26 (20) 49 (37) 54 (41) 2 (2)
Table 3 Self-reported Lupus quality of life scores
Domain Score
Physical health (8 items) 67
Pain (3 items) 47
Planning (3 items) 74
Intimate relationship (2 items) 71
Burden to others (3 items) 69
Emotional health (6 items) 75
Body image (5 items) 57
Fatigue (4 items) 62
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may be because many of the cutaneous features seen in
SLE are typically noted on the face and are photosensitive
in nature [33]. It remains unclear whether those skin path-
ologies reported on the feet (rash, blisters and chilblains)
were SLE-specific or SLE-non-specific. Finally, foot ulcer-
ation, while comparatively uncommon, was reported to
have been sometimes present by 14 %, a similar propor-
tion noted in a study on rheumatoid arthritis [34].
In spite of the frequency of reporting of foot complaints
and the difficulties associated with undertaking basic foot
care for some, comparatively few respondents indicated
they had seen a podiatrist. Clinical guidelines [35, 36] rec-
ommend podiatric input be provided, particularly for the
combination of foot pain and extra-articular features that
make people with SLE particularly at risk of foot complica-
tions. Comparatively few participants had been provided
with insoles, and a systematic review has demonstrated
some benefit from this type of intervention in other inflam-
matory arthropathies, such as rheumatoid arthritis [37].
Our findings need to be considered alongside a number
of limitations. Our response rate of 32 % was lower than
hoped, but in line with recent work utilising a similar meth-
odology [38]. SLE typically affects people from ethnic mi-
norities who may not have similar levels of health literacy
and may find questionnaires more complex to complete.
The questionnaire relies on self-reporting of foot com-
plaints and as highlighted previously, further clinical valid-
ation of our findings is required as some of our findings
may not only be due to SLE. Equally, self-reporting may
unreliable owing to an incorrect ‘self-diagnosis’. However, a
recent study reported high levels of agreement between
self-rpert and clinical examination for straight foward foot
complaints in people with rheumatoid arthritis [39]. It is
difficult to exclude the possibility of a responder bias; i.e.
participants’ with prevalent foot pain were more likely to
respond to this survey. There remains some reassurance in
the fact that some 55 % of respondents were not currently
experiencing foot pain and almost a quarter of our respon-
dents had never experienced foot pain, yet fully completed
the questionnaire. There is currently a lack of podiatric in-
tegration within rheumatology services and an unmet need
for podiatric foot care for people with inflammatory arth-
ritis in New Zealand [40]. Therefore, access to podiatry ser-
vice is not similar to equivalent services offered in the UK
and around the world. New Zealand has a higher propor-
tion of people of Maori and Pacific Island heritage than
other parts of the world. These groups are known to have a
higher incidence of SLE [6] and as such our findings may
not be fully transferrable. The mean age in our study is
higher than other cross-sectional epidemiological studies
[11, 12] and it is possible we have not fully captured youn-
ger participants’ perceptions. Using a cross-sectional survey,
there is inevitably considerable heterogeneity (and conse-
quently a large number of potential confounders) in the
study population, however to some extent this reflects the
varied nature of SLE.
Foot complaints can have serious sequelae in people
who are immuno-compromised, particularly where sys-
temic co-morbidities known to adversely affect foot
health such as poor peripheral vasculature co-exist. Fu-
ture work should seek to consider how the variables that
may affect foot pain are investigated together, as well as to
determine the risk factors associated with foot pain in
SLE. The use of alternative data capture mechanisms, (e.g.
utilising social media platforms) should also be consid-
ered, given the overall typically younger age profile associ-
ated with SLE. The current study has highlighted that
participants with SLE have an increased need for a range
of basic foot care services. Further work is also needed to
develop and validate a patient-reported outcome tool to
evaluate foot pain, impairment and disability in people
with SLE. This would better enable clinical trials evaluat-
ing podiatric interventions in SLE to be undertaken.
Conclusions
We have characterised the patterns and effects of foot
complaints in a group of people with SLE. Pain in the
joints of the feet was more common than extra-articular
features. Nevertheless, a wide range of extra articular
complaints was reported from vascular, neurological and
cutaneous origin. Foot complaints in SLE appear hetero-
geneous in nature, and may have a substantial negative
impact on participants’ mobility, quality of life and well-
being. There would seem to be a need for wider access
to specific foot care services and the development of a
patient-reported outcome tool to evaluate foot pain, im-
pairment and disability in people with SLE would be
valuable.
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